Porous drug matrices and methods of manufacture thereof

Details Porous drug matrices and methods of manufacture thereof Porous drug matrices and methods of manufacture thereof

2005-08-23

2005-08-23

Webman, Edward J. (Department: 1617)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Particulate form

C424S400000

Reexamination Certificate

active

06932983

ABSTRACT:
Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissolution of the drug in aqueous media. The drug matrices preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissolution following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration.

REFERENCES:
patent: 4818542 (1989-04-01), DeLuca et al.
patent: 5382437 (1995-01-01), Ecanow
patent: 5468598 (1995-11-01), Miller et al.
patent: 5470583 (1995-11-01), Na et al.
patent: 5500331 (1996-03-01), Czekai et al.
patent: 5510118 (1996-04-01), Bosch et al.
patent: 5513803 (1996-05-01), Czekai et al.
patent: 5518187 (1996-05-01), Bruno et al.
patent: 5518738 (1996-05-01), Eickhoff et al.
patent: 5534270 (1996-07-01), De Castro
patent: 5552160 (1996-09-01), Liversidge et al.
patent: 5560932 (1996-10-01), Bagchi et al.
patent: 5565188 (1996-10-01), Wong et al.
patent: 5569448 (1996-10-01), Wong et al.
patent: 5571536 (1996-11-01), Eickhoff et al.
patent: 5580579 (1996-12-01), Ruddy et al.
patent: 5587143 (1996-12-01), Wong
patent: 5591456 (1997-01-01), Franson et al.
patent: 5609998 (1997-03-01), Texter et al.
patent: 5622938 (1997-04-01), Wong
patent: 5657931 (1997-08-01), Nair et al.
patent: 5662279 (1997-09-01), Czekai et al.
patent: 5662883 (1997-09-01), Bagchi et al.
patent: 5665331 (1997-09-01), Bagchi et al.
patent: 5716642 (1998-02-01), Bagchi et al.
patent: 5718919 (1998-02-01), Ruddy et al.
patent: 5747001 (1998-05-01), Wiedmann et al.
patent: 5762961 (1998-06-01), Roser et al.
patent: 5919434 (1999-07-01), Dugstad et al.
patent: 5942253 (1999-08-01), Gombotz
patent: 5976574 (1999-11-01), Gordon
patent: 5985285 (1999-11-01), Titball et al.
patent: 6001336 (1999-12-01), Gordon
patent: 6423345 (2002-07-01), Bernstein et al.
patent: 6565885 (2003-05-01), Tarara et al.
patent: 2 136 704 (1995-05-01), None
patent: 37 13 326 (1987-10-01), None
patent: 0 655 237 (1995-05-01), None
patent: 1 265 615 (1972-03-01), None
patent: 98/31346 (1998-07-01), None
patent: WO 98/51282 (1998-11-01), None
patent: 99/56731 (1999-11-01), None
Adeyeye & Price, “Chemical, dissolution stability and microscopic evaluation of suspensions of ibuprofen and sustained release ibuprofen-wax microspheres,”J. Microencapsul.14(3):357-77 (1997).
Ahn, et al., “Enhancement of bioavailability of ketoprofen using dry elixir as a novel dosage form,”Drug Dev. Ind. Pharm.24(7):697-701 (1998).
Akade, et al., “Influence of polyethylene glycol 6000 and mannitol on the in-vitro dissolution properties of nitrofurantoin by the dispersion technique,”Pharmazie.41(12):849-51 )1986).
Akbarieh & Tawashi, “Morphic features of solid particles after micronization in the fluid energy mill,”Int. J. Pharm.35:81-89 (1987).
Allen, et al., “Dissolution rates of corticosteroids utilizing sugar glass dispersions,”J. Pharm. Sci.66(4):494-97 (1977).
Ansel, et al., “Pharmaceutical Dosage Forms and Drug Delivery Systems,” 6thEd., (Williams & Wilkins 1995).
Appel & Zentner, “Use of modified ethylcellulose lattices for microporous coating of osmotic tablets,”Pharm. Res.8(5):600-04 (1991).
Arias, “Dissolution properties and in vivo behaviour of triamterene in solid dispersions with polyethylene glycols,”Pharm. Acta. Helv.71(4):229-35 (1996).
Arias, et al., “The application of solid dispersion technique with D-mannitol to the improvement in oral absorption of triamterene.”J. Drug Target.2(1):45-51 (1994).
Arteaga, et al., “Dissolution velocity of different calcium preparations used in the clinical field,”Rev. Med. Chil.124(11):1325-33 (1996).
Badiger, et al., “Porogens in the preparation of microporous hydrogels based on poly(ethylene oxides),”Biomaterials14:1059-63 (1993)
Bodmeier & Paeratakul, “Spherical agglomerates of water-insoluble drugs,”J. Pharm. Sci.78(11):964-67 (1989).
Borgstrom, et al., “In vitro and in vivo evaluation of controlled-release and enteric-coated formulations of sodium salicylate,”Biopharm. Drug Dispos.5(3):261-72 (1984).
Buckton, et al., “The effect of comminution technique on the surface energy of a powder,”Int. J. Pharm.47:121-28 (1998).
Cardorniga, et al., “In vitro evaluation of the dissolution rate of crystalline suspensions destined to intramuscular administration,”Eur. J. Drug Metab. Pharmacokinet.Spec No. 3:379-84 (1991).
Chaumeil, et al., “Micronization: a method of improving the bioavailability of poorly soluble drugs,”Meth. Find. Exp. Clin. Pharmacol.20(3):211-15 (1998).
Chen & Hao, “Factors affecting zero-order release kinetics of porous gelatin capsules,”Drug Dev. Ind. Pharm.24(6):557-62 (1998).
Chen & Hao, “In vitro performance of floating sustained-release capsule of verapamil,”Drug Dev. Ind. Pharm.24(11):1067-72 (1998).
Chiou & Riegelman, “Oral absorption of griseofulvin in dogs: increased absorption via solid dispersion in polyethylene glycol 6000,”J. Pharm. Sci.59(7):937-42 (1970).
Chiou & Riegelman, “Pharmaceutical applications of solid dispersion systems,”J. Pharm. Sci.60:1281-302 (1971).
Chiou, et al., “Enhancement of dissolution rates of poorly water-soluble drugs by crystallization in aqueous surfactant solutions I: Sulfathiazole, Prednisone, and Chloramphenicol,”J. Pharm. Sci.65:1702-04 (1976).
Christensen, et al., “Storage of polyvinylpyrrolidone (PVP) in tissues following long-term treatment with a PVP-containing vasopressin preparation,”Act. Med. Scand.204:295-98 (1978).
Corrigan & Holohan, “Amorphous spray-dried hydroflumethiazide-polyvinylpyrrolidone systems: physiochemical properties,”J. Pharm. Pharmacol.36(4):217-21 (1984).
De Almeida, et al., “Modeling dissolution of sparingly soluble multisized powders,”J. Pharm. Sci.86:726-32 (1997).
Dordundo, et al., “Physical stability of solid dispersions containing triamterene or temazepam in polyethylene glycols,”J. Pharm. Pharmacol.49(4):390-96 (1997).
Dressman & Fleisher, “Mixing-tank model for predicting dissolution rate control or oral absorption,”J. Pharm. Sci.75(2):109-16 (1986).
Eichman & Robinson, “Mechanistic studies on effervescent-induced permeability enhacement,”Pharm. Res.15(6):925-30 (1998).
El-Fattah, et al., “Enhancement of dissolution rate of hydrochlorothiazide via solid dispersion,”Pharmazie.41(11):790-93 (1986).
Feinstein & Sciarra, “Development and evaluation of a dexamethasone timed-release aerosol formulation,”J. Pharm. Sci.64:408-13 (1975).
Fenimore & Loy, “Injectible dispersion of9-tetrahydrocannabinol in saline using polyvinyl pyrrolidone,”J. Pharm. Pharmac.23:310 (1971).
Ford, “The current status of solid dispersions,”Pharm. Act. Helv.61:69-88 (1986).
Freitas & Müller, “Spray-drying of solid lipid nanoparticles (SNL™),”Eur. J. Pharm. Biopharm.46(2):

Affiliated with

Also associated with

Rating

Porous drug matrices and methods of manufacture thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Porous drug matrices and methods of manufacture thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Porous drug matrices and methods of manufacture thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3458141